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BACKGROUND: 8-Hydroxydeoxyguanosine (8-oxodG) is the commonly used marker of oxidative stress-derived DNA damage.
8-OxodG formation is regulated by local antioxidant capacity and DNA repair enzyme activity. Earlier studies have reported
contradictory data on the function of 8-oxodG as a prognostic factor in different cancer types.
METHODS: We assessed pre-operative serum 8-oxodG levels with an enzyme-linked immunosorbent assay in a well-defined series of
173 breast cancer patients. 8-OxodG expression in the nuclei of cancer cells from 150 of these patients was examined by
immunohistochemistry.
RESULTS: The serum 8-oxodG levels and immunohistochemical 8-oxodG expression were in concordance with each other (Po0.05).
Negative 8-oxodG immunostaining was an independent prognostic factor for poor breast cancer-specific survival according to the
multivariate analysis (Po0.01). This observation was even more remarkable when ductal carcinomas only (n¼140) were considered
(Po0.001). A low serum 8-oxodG level was associated statistically significantly with lymphatic vessel invasion and a positive lymph
node status.
CONCLUSIONS: Low serum 8-oxodG levels and a low immunohistochemical 8-oxodG expression were associated with an aggressive
breast cancer phenotype. In addition, negative 8-oxodG immunostaining was a powerful prognostic factor for breast cancer-specific
death in breast carcinoma patients.
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Reactive oxygen species (ROS), despite being products of normal
cellular metabolism, are considered to have a substantial influence
on the development of cancer, in part, because of their ability to
react with DNA. For example hydroxyl radical (
KOH) can react
with pyrimidines, purines and chromatin protein resulting in base
modifications, genomic instability and alterations in gene expres-
sion. These reactions in connection with oncogenes or tumour
suppressor genes may result in the initiation of cancer (Loft and
Poulsen, 1996). Several recent studies have shown high ROS levels
in carcinoma cells compared with the surrounding healthy tissue
(reviewed in Karihtala and Soini, 2007). Under normal conditions,
ROS are maintained within narrow boundaries by scavenging
systems, such as superoxide dismutases, peroxiredoxins (Prx) and
glutathione-related antioxidant defences. Consequently, when the
amount of ROS exceeds the capacity of the ROS scavenging
systems, oxidative stress occurs and this imbalanced redox status
leads to an increase in damage to DNA.
A direct measurement of ROS is challenging because of their
short lifetime and immediate reaction with redox state regulating
components. For instance, it has been estimated that the lifespan
of
KOH, the most harmful ROS, is o1ns (Valko et al, 2004).
Therefore, a useful method to assess ROS is the use of antibodies
against the specific ‘footprints’ of oxidative damage. 8-Hydro-
xydeoxyguanosine (8-oxodG) is a specific marker of 20-deoxygua-
nosine damage after ROS attack to DNA. 8-OxodG is one of the
most widely used oxidative stress biomarkers, and it can be
measured with immunohistochemistry and, for example by
enzyme-linked immunosorbent assay (ELISA) or high pressure
liquid chromatography, with mass spectrometric or electrochemi-
cal detection (HPLC-MS/MS; HPLC-EC) in serum or urine samples
(Cooke et al, 2008). There are currently no data as to whether
systemic 8-oxodG levels are associated with 8-oxodG modifications
in situ in any disease or whether serum or immunohistochemical
assessment of 8-oxodG could be used as a prognostic factor in
breast cancer.
In this study, we analysed serum 8-oxodG levels and 8-oxodG
tissue expression from breast carcinoma patients and correlated
the results with clinicopathological parameters such as the stage,
grade and lymphatic and blood vessel invasion status. The
function of 8-oxodG as a prognostic factor in breast cancer and
correlation between serum 8-oxodG levels and 8-oxodG breast
carcinoma tissue expression was evaluated.
MATERIALS AND METHODS
The study material consisted of 173 pre-operative venous blood
samples from breast carcinoma patients, which were acquired
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sfrom the files of the Department of Oncology, Oulu University
Hospital from 2003 to 2005. In addition, we were able to acquire
150 out of 173 tumour blocks from these patients for immuno-
histochemical analysis. The tumour blocks were collected from the
archives of the Department of Pathology, Oulu University Hospital.
The study was approved by the Local Ethics Committee.
Blood samples were taken before primary operations and serum
samples were stored in polypropylene or polystyrene tubes at
 801C until the time of analysis. The breast cancer tissue samples
were fixed in neutral formalin and embedded in paraffin. The
malignancy grades in the cancerous lesions were determined
according to the WHO classification (Tavassoli and Devilee, 2003)
by pathologist (SK). The material comprised 140 ductal carcino-
mas, 25 lobular carcinomas and 8 other types of breast carcinomas.
The clinical data were sourced from the records of Oulu University
Hospital. The most important patient and tumour characteristics
are shown in Table 1. The mean follow-up time of the subjects was
40.5 months.
The serum levels of 8-oxodG were determined using an ELISA
using the Highly Sensitive 8-OHdG kit, which was obtained
from the Japan Institute for the Control of Aging, Fukuroi, Japan.
The kit uses an anti 8-oxodG monoclonal antibody (clone N45.1),
which is highly specific for 8-oxodG. The ELISA assay was
performed according to the manufacturer’s instructions with a few
divergences. At first, we pre-processed all serum samples using
Millipore Microcon filters. Filters were damped with 100mlo f
distilled water and subsequently centrifuged in 14.000g for 5min.
Then filters were turned around and centrifuged for another
5min to remove remaining water. Damped filters were moved to
new tubes and 200ml of serum sample was added into each tube
and then centrifuged for 30min in 14.000g. Next, the primary
antibody was reconstituted with the primary antibody solution.
Then 50ml of sample or standard were added to wells, doing
duplicate for each. After that, 50ml of reconstituted primary
antibody was added to each well. Plate was shaken and covered
with adhesive strip and then incubated at 41C for over night.
After incubation, the contents of the wells were poured off and
each well was washed with 250ml of washing solution three times.
Then secondary antibody was reconstituted with the secondary
antibody solution; 100ml of constituted secondary antibody was
added to each well. Next, the plate was shaken, covered with
adhesive strip and then incubated for 1h at room temperature.
Washing was repeated at the end of the incubation period.
After that, a substrate solution was prepared and 100mlo fi t
was added to each well and the plate was shook. The plate
was incubated in the dark for 15min at room temperature. Then
100ml of reaction terminating solution was added to each well
and the plate was shook. Absorbances were measured at 450nm in
a plate reader and standard curve was used to determine the
amount of 8-oxodG in samples. We assayed the duplicates of
each sample and used also the outermost wells of the microtiter
plate. With this method, we were able to assay 41 samples in one
plate. The 8-oxodG concentrations from the duplicate samples
were extremely close to each other throughout the analysis, and
if they differed to 410%, they were assayed again. Four out of
173 samples were re-assayed because of over 10% variance
between duplicates.
For immunohistochemistry, the paraffin-embedded breast
lesions were first sectioned on slides of 4mm thickness and placed
on SuperFrostPlus glass (Menzel–Gla ¯ser, Germany). To remove the
paraffin, they were soaked in xylene and then rehydrated in a
graded alcohol series. They were heated in a microwave oven in
10mm of citric acid monohydrate for 10min to predigest the
sections, and then chilled at room temperature. The sections were
immersed in 3% hydrogen peroxide in methanol for 15min to
consume the endogenous peroxide. The slides were incubated
with a 1:125 primary antibody dilution against 8-oxodG
(Mouse monoclonal 8-oxodG antibody, Gentaur, Belgium)
overnight at þ41C. Both ELISA kit and immunostainings were
based on the same 8-oxodG antibody (N45.1) (Toyokuni et al,
1997). Immunostaining was carried out by using a biotinylated
secondary antibody 1:400 dilution with an avidin–biotin–
peroxidase complex (Dakopatts, Glostrup, Denmark). Aminoethyl
carbazole (Zymed Laboratories Inc., South San Francisco,
California, USA) was used as a chromogen. Immersed in
2% ammonia water, Meyer’s haematoxylin was used for counter-
staining, and in the end, the sections were mounted with Immu-
Mount (Shandon, Pittsburgh, PA, USA).
The intensity of the 8-oxodG immunostainings from the
nuclei of cancer cells was evaluated by dividing the staining
reaction into four groups:  ¼negative immunostaining (o5% of
tumour cells showing nuclear positivity), þ¼weak immuno-
staining (5–20% of tumour cells showing nuclear positivity),
þþ¼moderate immunostaining (21–80% of tumour cells
showing nuclear positivity) and þþþ¼strong immunostaining
(480% of tumour cells showing nuclear positivity). For statistical
analysis, we divided the immunostaining results into two groups:
negative ( ) and positive (þ, þþ, þþþ) immunostaining.
The distribution of the immunostaining groups is shown in
Table 2.
Table 1 Patient and tumour characteristics
Ductal
carcinoma
(n¼140)
Lobular
carcinoma
(n¼25)
Other
carcinomas
(n¼8)
Total
(n¼173)
Average age (years) 56.4±12.1 58.2±16.7 66.5±13.3 57.1±13.0
Grade
I 18 (12.9%) 2 (8%) 7 (87.5%) 26 (15.6%)
II 64 (45.7%) 19 (76%) 1 (12.5%) 83 (48.6%)
III 58 (41.4%) 4 (16%) 0 (0%) 62 (35.8%)
T
1 89 (63.6%) 16 (64%) 5 (62.5%) 110 (63.6%)
2 44 (31.4%) 8 (32%) 3 (37.5%) 55 (31.8%)
3+4 7 (5%) 1 (4%) 0 (0%) 8 (4.7%)
N
0 75 (53.6%) 14 (56%) 8 (100%) 97 (56.1%)
1 58 (41.4%) 8 (32%) 0 (0%) 66 (38.2%)
2 7 (5%) 3 (12%) 0 (0%) 10 (5.8%)
HER-2
Positive 20 (14.3%) 2 (8%) 0 (0%) 22 (12.7%)
Negative 120 (85.7%) 23 (92%) 8 (100%) 151 (87.3%)
Estrogen receptor
Positive 107 (76.4%) 25 (100%) 8 (100%) 140 (80.9%)
Negative 33 (23.6%) 0 (0%) 0 (0%) 33 (19.1%)
Progesterone receptor
Positive 90 (64.3%) 19 (76%) 7 (87.5%) 116 (67.1%)
Negative 50 (35.7%) 6 (24%) 1 (12.5%) 57 (32.9%)
Lymphatic vessel invasion
Yes 15 (10.7%) 0 (0%) 1 (12.5%) 16 (9.2%)
No 119 (85.0%) 25 (100%) 7 (87.5%) 151 (87.3%)
Unknown 6 (4.3%) 6 (3.5%)
Blood vessel invasion
Yes 9 (6.4%) 0 (0%) 0 (0%) 9 (5.2%)
No 125 (89.3%) 25 (100%) 8 (100%) 158 (91.3%)
Unknown 6 (4.3%) 6 (3.5%)
Treated with
Radiotherapy 131 (93.6%) 23 (92%) 4 (50%) 158 (91.3%)
Chemotherapy 75 (53.6%) 7 (28%) 0 (0%) 82 (47.4%)
Hormonal therapy 60 (42.9%) 10 (40%) 0 (0%) 70 (40.5%)
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sSPSS 15.0 for Windows and R-language were used for statistical
analysis. The significance of the associations was defined using
the Spearman’s test, Mann–Whitney U-test and Pearson w
2-test
with Fisher’s two-sided exact test for 8-oxodG ELISA and 8-oxodG
immunohistochemistry, respectively. Survival was analysed with
the Kaplan–Meier curve with log-rank, Tarone–Ware and Breslow
tests. Cox multivariate regression analysis was used for multi-
variate analysis. The probability values o0.05 were considered
significant. We also cooperated with a statistics expert as needed.
RESULTS
The 8-oxodG serum levels and tissue expression of the whole
patient group, and separately of the patients with ductal carci-
noma, were compared with several known tumour characteristics.
The presence of lymphatic invasion, blood vessel invasion, lymph
node metastases, expression of oestrogen receptor, progesterone
receptor, HER-2, Ki-67 and p53 were classified as either positive or
negative for statistical analyses. The grading and tumour size were
divided into the following subgroups: grade I group, grade II–III
group, T1 group and T2–4 group.
When the characteristics were compared within the whole
patient group, the lower serum 8-oxodG levels were associated
with lymphatic vessel invasion (Po0.05) and positive lymph node
status (Po0.05) (Table 3). Among the ductal carcinoma patients,
similarly low serum 8-oxodG levels correlated with poor differ-
entiation (Po0.05), lymphatic and blood vessel invasions
(Po0.05) and node status (Po0.01). Serum 8-oxodG was not a
statistically significant prognostic factor in either the whole or the
ductal cancer patient groups.
The 8-oxodG immunostaining localised subcellularly to nuclei
(Figure 1). Negative 8-oxodG immunostaining correlated with
negative HER-2 (Po0.05) and p53 (Po0.05) expression within the
whole study group. In addition, negative 8-oxodG immuno-
staining was associated with positive node status among ductal
carcinoma patients (Po0.05). The 8-oxodG levels from serum
and 8-oxodG tissue expression correlated positively with each
other according to the Spearman’s test (Po0.05, correlation
coefficient 0.163). Neither serum nor immunohistochemical
8-oxodG were associated with the patient age or menopausal
status.
Patients with negative 8-oxodG immunostaining had a higher
risk of breast cancer-specific death compared with patients with
positive 8-oxodG immunostaining (Kaplan–Meier, log-rank ana-
lysis Po0.01; Figure 2). Survival statistics are shown in Table 4. In
the Cox multivariate analysis, a negative 8-oxodG immunohisto-
chemistry was an independent prognostic factor of poor survival
when tumour size, node status, grade, Ki-67, HER-2, p53 and
receptor status were taken into account.
DISCUSSION
In this study, we show for the first time that negative 8-oxodG
immunostaining in breast cancer cells is an independent prog-
nostic factor for poorer prognosis and that low serum and tissue
levels of 8-oxodG are characteristic of more aggressive breast
cancer. 8-OxodG is one of the most widely used biomarkers of
oxidative stress, mainly because of its abundance in DNA and also
Table 3 Mean serum 8-oxodG levels and s.d. in the groups of
conventional prognostic factors
Mean 8-oxodG (ngml
–1) P-value
Tumor size (T)
1 0.18±0.13 NS
2–4 0.15±0.11
Nodal status (N)
0 0.18±0.12 Po0.05
1–2 0.15±0.13
Grade
1–2 0.17±0.12 NS
3 0.17±0.13
Lymphatic vessel invasion
Yes 0.12±0.09 Po0.05
No 0.17±0.13
Blood vessel invasion
Yes 0.10±0.04 NS
No 0.17±0.13
ER expression
Positive 0.16±0.12 NS
Negative 0.19±0.14
PR expression
Positive 0.16±0.12 NS
Negative 0.19±0.13
Ki-67
0–2 0.16±0.12 NS
3 0.19±0.14
Her-2
Positive 0.15±0.09 NS
Negative 0.17±0.13
Histology
Ductal 0.17±0.13 NS
Other 0.16±0.13
Abbreviations: ER¼oestrogen receptor; NS¼no statistical significance; PR¼
progesterone receptor; 8-oxodG¼8-hydroxydeoxyguanosine.
Figure 1 An example of highly positive (A) (magnification  210) and
negative (B) (magnification  105) 8-oxodG immunostaining.
Table 2 Distribution of 8-oxodG immunostaining
All patients (n¼150) Ductal carcinomas (n¼123)
  23 (15.3%) 17 (13.8%)
+ 23 (15.3%) 23 (18.7%)
++ 64 (42.7%) 53 (43.1%)
+++ 40 (26.7%) 30 (24.4%)
Abbreviation: 8-oxodG¼8-hydroxydeoxyguanosine.
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Compared with other bases, guanine most readily undergoes an
oxidative attack in the presence of ROS (Peoples and Karnes,
2005). 8-OxodG can induce GC-TA transversion mutations
particularly during DNA replication and thus, if these oxidative
lesions are not repaired, they can become mutagenic (Peoples and
Karnes, 2005). There is a rather broad consensus that extracellular
8-oxodG levels are not affected by diet, cell death or artefactual
formation (Cooke et al, 2005). However, this is the first study to
show that oxidative stress observed in cancer cells reflects a good
correlation to the serum 8-oxodG levels. Therefore, it seems that
serum 8-oxodG in breast cancer patients mainly originates from
tumour tissue.
Earlier, many studies examining oxidatively damaged DNA in
carcinogenesis have discovered augmented 8-oxodG levels in
either the urine or tumour tissue DNA compared with the healthy
tissue. For example, in studies on breast carcinomas, the 8-oxodG
levels have been reported as being 8 to 17 times higher in
comparison with those in healthy breast tissue (Matsui et al, 2000).
Elevated levels of 8-oxodG from cancer patients compared with
healthy subjects have also been observed in lung cancer (Vulimiri
et al, 2000; Shen et al, 2007), basal cell carcinoma (Nishigori et al,
2005), bladder cancer (Kaczmarek et al, 2005), acute lymphoblastic
leukaemia (Sentu ¨rker et al, 1997), colorectal cancer (Oliva et al,
1997), high grade cervical dysplasia (Romano et al 2000), renal
cell carcinoma (Okamoto et al, 1994), prostate cancer (Miyake
et al, 2004), gastric intestinal metaplasia (Farinati et al, 2008) and
gastric adenocarcinoma (Lee et al, 1998). Evidence from these
studies suggests that elevated 8-oxodG levels in these malignant
or premalignant diseases compared with healthy individuals would
be a sign of increased oxidative stress, impaired antioxidant
defence or inadequate repair of oxidatively damaged DNA.
A recent study showed a highly significant decrease of 8-oxodG
serum levels after breast cancer surgery compared with pre-
operative levels (Cho et al, 2009). However, there are also some
reports that have found no difference in the 8-oxodG levels
between cancer patients and healthy subjects (Nagashima et al,
1995; Jałoszyn ˜ski et al, 2003).
In this study, low immunohistochemical expression and low
pre-operative serum 8-oxodG levels were strongly associated with
conventional prognostic factors for aggressive breast cancer such
as positive lymph node status and lymphovascular invasion. This
significant association was even more obvious among ductal
carcinomas, which is the main histological subtype of breast
cancer with a highly variable prognosis and, therefore, more
accurate prognostic factors are needed especially for this
histological breast cancer subtype. In parallel with this, the
presence of 8-oxodG immunostaining correlated with positive
HER-2 status and high p53 expression. HER-2 is a one of the most
widely used tumour markers in breast cancer, and HER-2 gene
amplification results in poor prognosis, resistance to hormonal
therapies and generally to more aggressive breast cancer
phenotype (Slamon et al, 1987; Ross et al, 2009). p53 is a tumour
suppressor protein, whose physiological function is highly
essential in safeguarding DNA integrity (Barnes and Camplejohn,
1996). The co-expressions between 8-oxodG and p53 and HER-2
are probably because of the nature of 8-oxodG as a marker of
oxidative stress-derived DNA mutations in general and suggest
that ROS has a function in the formation of HER-2 and p53
mutations. Earlier, ROS-derived GC-TA transversions have been
observed in the p53 gene in vivo in lung and liver cancers (Hussain
et al, 2000; Cooke et al, 2006).
Furthermore, according to our results, negative 8-oxodG
immunostaining from tumour tissue could be used as an
independent prognostic factor for poor breast cancer-specific
survival. Earlier, two groups have reported that low 8-oxodG levels
either in tumour tissue or in urine of breast cancer patients are
associated with a higher stage or grade (Matsui et al, 2000; Kuo
et al, 2007). In both of these studies, 8-oxodG levels were elevated
in cancer patients compared with healthy controls. However, these
studies were smaller than ours and no associations between
8-oxodG and survival were reported. In a study by Dincer et al
(2007), the 8-oxodG plasma levels were significantly higher in
controls than in gastric and colon carcinoma patients, which is
also in line with our results. However, high 8-oxodG levels from
tumour tissue DNA have also been reported as an independent
prognostic factor of poor survival in lung cancer and hepato-
cellular carcinoma (Matsumoto et al, 2003; Shen et al, 2007). This
emphasizes the diverse prognostic function of 8-oxodG in different
malignancies.
There are several possible mechanisms behind the inverse
association of 8-oxodG levels and tumour aggressiveness. Low
serum, plasma or urine levels of 8-oxodG can be a sign of
enfeebled repair of oxidatively damaged DNA or enhanced
antioxidant defence rather than low ROS production. The main
repair enzyme for 8-oxodG is human 8-oxoguanine DNA glyco-
sylase 1 (hOGG1) and its proper function is crucial for the preven-
tion of G to T transversion mutations (Hirano, 2008). Reduced
hOGG1 levels significantly increase relative risk for initiation
of carcinomas (Paz-Elizur et al, 2003, 2006). With impaired
hOGG1 function, cells are not able to cleave damaged guanosine
from DNA, which results in lower 8-oxodG levels in extracellular
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Figure 2 Kaplan–Meier curves showing breast cancer-specific survival when immunohistochemical 8-oxodG staining is divided into either negative or
positive: (A) all carcinomas (log-rank Po0.01) and (B) ductal carcinomas only (log-rank Po0.001).
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sfluids. However, defects in DNA repair do not explain low 8-oxodG
expression in the tumour tissue of the most aggressive breast
carcinomas. High ROS production in tumour tissue promotes
the over-expression of antioxidant proteins, such as thioredoxins
and Prx, which are associated with malignant transformation in
breast cancer (Karihtala et al, 2003; Turunen et al, 2004). In
addition, promoted antioxidant defence in tumour tissue could
offer a growth advantage to cancer cells by avoiding apoptosis and
necrosis caused by ROS. Overproduced antioxidant enzymes
would prevent ROS interaction with DNA leading to decreased
formation of 8-oxodG at tissue level as suggested by the current
results. Transcription factor NF-E2-related factor 2 (Nrf2), the
major up-regulator of multiple antioxidant enzymes (e.g. perox-
iredoxin I, thioredoxin reductase), has a highly important
function in eliminating ROS from the cells. On the other hand,
Nrf2 up-regulation, which is commonly seen in chemoresistant
cell lines, may provide growth advantage to cancer cells during
oncological treatments (Lau et al, 2008, Singh et al, 2008).
Although the clinical data is currently lacking from breast
cancer patients, Nrf2 up-regulation and consequent antioxidant
enzyme induction and chemoresistance may explain why the
patients with the worst prognosis have low 8-oxodG levels at the
initial situation.
The function of oxidative stress has also been studied in some
non-malignant diseases (Evans and Cooke, 2006). Interestingly,
low levels of 8-oxodG have been reported in the urine of systemic
lupus erythematosus patients and in cerebrospinal fluid of patients
with Alzheimer’s disease when compared with healthy subjects
(Evans and Cooke, 2006; Farinati et al, 2008). These authors also
concluded that low 8-oxodG levels should be taken as evidence of
impaired DNA repair of 8-oxodG.
We conclude that immunohistochemical 8-oxodG expression is
associated with the serum 8-oxodG levels among breast cancer
patients. Low 8-oxodG levels both in serum and in breast cancer
cells strongly indicate a more aggressive disease, especially in
ductal carcinomas. Negative 8-oxodG immunohistochemical stain-
ing is a powerful prognostic factor in breast carcinoma patients.
The mechanism behind these results offers an attractive topic for
future studies.
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NS¼no statistical significance; PR¼progesterone receptor; 8-oxodG¼8-hydro-
xydeoxyguanosine.
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